Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
Ixekizumab Prefilled Syringe
DRUG
2 trials
Sponsors
Eli Lilly and Company
, Massachusetts Eye Research and Surgery Institution
Conditions
Panuveitis
Plaque Psoriasis
Uveitis, Anterior
Uveitis, Intermediate
Uveitis, Posterior
Phase 3
Evaluation of Ixekizumab Using Auto-Injector or Prefilled Syringe in Participants With Moderate to Severe Plaque Psoriasis
Completed
NCT01777191
Eli Lilly and Company
Plaque Psoriasis
Start: 2013-03-31
End: 2015-05-31
Updated: 2019-09-30
Phase 4
Ixekizumab for the Management of Refractory Non-Infectious Uveitis: A Proof-of-Concept Study
NCT06085079
Massachusetts Eye Research and Surgery Institution
Panuveitis, Uveitis, Anterior, Uveitis, Intermediate +1
Start: 2022-06-01
End: 2024-12-30
Target: 20
Updated: 2023-10-16
Related Papers
Phase 3, open‐label, randomized study of the pharmacokinetics, efficacy and safety of ixekizumab following subcutaneous administration using a prefilled syringe or an autoinjector in patients with moderate‐to‐severe plaque psoriasis (<scp>UNCOVER</scp>‐A)
Journal of the European Academy of Dermatology and Venereology
2016-08-08
41 citations